Catalentincis A Global Leader In Pharmaceutical Developmentmanufacturingand Supply Chain Solutionsbased In Somersetnew Jerseyas A Subsidiary Of Novo Holdings A S Since 2024The Company Operates 53 Facilities Across Four Continents And Employs Approximately 16 900 Peoplecatalent Plays A Vital Role In The Pharmaceutical Industrycontributing To Over Half Of Fda Approved Products In The Last Decade And Producing 70 Billion Doses Annually For Around 8 000 Products Founded In 2007Catalent Specializes In Drug Delivery Technologiesdevelopment And Manufacturingclinical Solutionsand Biologics And Gene Therapyits Offerings Include Softgel Capsulesorally Disintegrating Tabletsand Advanced Manufacturing Capabilities For Monoclonal Antibodies And Vaccinesthe Company Partners With Leading Pharmaceutical And Biotech Firmsproviding Essential Services For Rapid Scale Upparticularly During Public Health Crisesin 2024Catalent Reported $4 38 Billion In Revenuereflecting Its Extensive Operational Scale And Commitment To Innovation In The Pharmaceutical Sector
United States
Japan
